This approval is based on the single-arm phase-2 CHECKMATE-027 study (#msg-125671046), and it is not restricted by PD-L1 expression.
This is the CHMP’s first PD-(L)1 approval in this indication. In the US, Opdivo and Roche’s Tecentriq have accelerated approval in this indication (#msg-128386168, #msg-130552759).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.